For instance, wildtype TP53 is required in the anti-cancer actions of CX-5461 [28, 29] and sorafenib [30] (both P of ΔIC50 ~ 0 in our data; Fig. 4b), sensitizes various cancer cells to bortezomib [31] (P = 4.4 × 10− 308; Fig. 4b), and enhances phenformin-induced growth inhibition and apoptosis [32] (P = 2.0 × 10− 241; Fig. 4b). The gene discussed is TP53; the disease is cancer.